1887

Journal of Medical Microbiology logo

Volume 58, Issue 9

Quest for a broad-range vaccine against serogroup B: implications of genetic variations of the surface-exposed proteins Free

Abstract

Despite the development of new vaccine formulations using new biotechnology resources to combat emerging and re-emerging diseases, serogroup B meningococcal disease is still a worldwide burden, accounting for many deaths and disabilities every year. The successful approach of coupling a polysaccharide (PS) with a carrier protein in order to increase long-lasting immunity could not be exploited against B because of the limitations of using the capsular PS of serogroup B meningococci. Tailor-made vaccines based on exposed proteins were shown to be a promising approach to overcome these flaws. However, the continuous adaptation of surface meningococcal structures to the external environment has led to genetic shifts of potential vaccine-target epitopes, hampering the quest for a broad-range vaccine that could be used against all serogroups, especially against serogroup B.

  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.011189-0
2009-09-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/9/1127.html?itemId=/content/journal/jmm/10.1099/jmm.0.011189-0&mimeType=html&fmt=ahah

References

  1. Beernink P. T., Leipus A., Granoff D. M. 2006; Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 13:758–763 [CrossRef]
     [Google Scholar]
  2. Beernink P. T., Welsch J. A., Harrison L. H., Leipus A., Kaplan S. L., Granoff D. M. 2007; Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 195:1472–1479 [CrossRef]
     [Google Scholar]
  3. Bernardini G., Braconi D., Martelli P., Santucci A. 2007; Postgenomics of Neisseria meningitidis for vaccines development. Expert Rev Proteomics 4:667–677 [CrossRef]
     [Google Scholar]
  4. Bisgard K. M., Kao A., Leake J., Strebel P. M., Perkins B. A., Wharton M. 1998; Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 4:229–237 [CrossRef]
     [Google Scholar]
  5. Brandtzaeg P., Van Deuren M. 2002; Current concepts in the role of the host response in Neisseria meningitidis septic shock. Curr Opin Infect Dis 15:247–252 [CrossRef]
     [Google Scholar]
  6. Comanducci M., Bambini S., Caugant D. A., Mora M., Brunelli B., Capecchi B., Ciucchi L., Rappuoli R., Pizza M. 2004; NadA diversity and carriage in Neisseria meningitidis . Infect Immun 72:4217–4223 [CrossRef]
     [Google Scholar]
  7. de Filippis I., do Nascimento C. R., Clementino M. B. M., Sereno A. B., Rebelo C., Souza N. N., Riley L. W. 2005; Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis 51:85–90 [CrossRef]
     [Google Scholar]
  8. Dyet K. H., Martin D. R. 2005; Sequence variation in the porB gene from B : P1.4 meningococci causing New Zealand's epidemic. J Clin Microbiol 43:838–842 [CrossRef]
     [Google Scholar]
  9. Feil E. J., Maiden M. C., Achtman M., Spratt B. G. 1999; The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis . Mol Biol Evol 16:1496–1502 [CrossRef]
     [Google Scholar]
  10. Frasch C. E. 2005; Recent developments in Neisseria meningitidis group A conjugate vaccines. Expert Opin Biol Ther 5:273–280 [CrossRef]
     [Google Scholar]
  11. Gardner P. 2006; Clinical practice. Prevention of meningococcal disease. N Engl J Med 355:1466–1473 [CrossRef]
     [Google Scholar]
  12. Giuliani M. M., Santini L., Brunelli B., Biolchi A., Aricò B., Di Marcello F., Cartocci E., Comanducci M., Masignani V. other authors 2005; The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73:1151–1160 [CrossRef]
     [Google Scholar]
  13. Giuliani M. M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A. other authors 2006; A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834–10839 [CrossRef]
     [Google Scholar]
  14. Granoff D. M., Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., Guarnieri V., Seid R. C., Shan A. other authors 1998; Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160:5028–5036
     [Google Scholar]
  15. Halperin S. A., Langley J. M., Smith B., Wunderli P., Kaufman L., Kimura A., Martin D. 2007; Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25:450–457 [CrossRef]
     [Google Scholar]
  16. Hammitt L. L., Block S., Hennessy T. W., Debyle C., Peters H., Parkinson A., Singleton R., Butler J. C. 2005; Outbreak of invasive Haemophilus influenzae serotype a disease. Pediatr Infect Dis J 24:453–456 [CrossRef]
     [Google Scholar]
  17. Hodgson A., Forgor A. A., Chandramohan D., Reed Z., Binka F., Bevilacqua C., Boutriau D., Greenwood B. 2008; A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 3:e2159 [CrossRef]
     [Google Scholar]
  18. Hou V. C., Moe G. R., Raad Z., Wuorimaa T., Granoff D. M. 2003; Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71:6844–6849 [CrossRef]
     [Google Scholar]
  19. Jacobsson S., Thulin S., Mölling P., Unemo M., Comanducci M., Rappuoli R., Olcén P. 2006; Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24:2161–2168 [CrossRef]
     [Google Scholar]
  20. Jódar L., LaForce F. M., Ceccarini C., Aguado T., Granoff D. M. 2003; Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361:1902–1904 [CrossRef]
     [Google Scholar]
  21. Koeberling O., Welsch J. A., Granoff D. 2007; Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived neisserial antigen 1870. Vaccine 25:1912–1920 [CrossRef]
     [Google Scholar]
  22. Koeberling O., Seubert A., Granoff D. M. 2008; Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198:262–270 [CrossRef]
     [Google Scholar]
  23. Maiden M. C., Malorny B., Achtman M. 1996; A global gene pool in the neisseriae. Mol Microbiol 21:1297–1298 [CrossRef]
     [Google Scholar]
  24. Martin S. L., Borrow R., Van Der Ley P., Dawson M., Fox A. J., Cartwright K. A. 2000; Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18:2476–2481 [CrossRef]
     [Google Scholar]
  25. Mitka M. 2005; New vaccine should ease meningitis fears. JAMA 293:1433–1434 [CrossRef]
     [Google Scholar]
  26. Moe G. R., Granoff D. M. 2001; Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int Rev Immunol 20:201–220 [CrossRef]
     [Google Scholar]
  27. Moe G. R., Zuno-Mitchell P., Hammond S. N., Granoff D. M. 2002; Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70:6021–6031 [CrossRef]
     [Google Scholar]
  28. Morelli G., Malorny B., Müller K., Seiler A., Wang J. F., del Valle J., Achtman M. 1997; Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 25:1047–1064 [CrossRef]
     [Google Scholar]
  29. Morley S. L., Pollard A. J. 2001; Vaccine prevention of meningococcal disease, coming soon?. Vaccine 20:666–687 [CrossRef]
     [Google Scholar]
  30. Norheim G., Aase A., Caugant D. A., Høiby E. A., Fritzsønn E., Tangen T., Kristiansen P., Heggelund U., Rosenqvist E. 2005; Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis . Vaccine 23:3762–3774 [CrossRef]
     [Google Scholar]
  31. O'Dwyer C. A., Reddin K., Martin D., Taylor S. C., Gorringe A. R., Hudson M. J., Brodeur B. R., Langford P. R., Kroll J. S. 2004; Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 72:6511–6518 [CrossRef]
     [Google Scholar]
  32. Oliver K. J., Reddin K. M., Bracegirdle P., Hudson M. J., Borrow R., Feavers I. M., Robinson A., Cartwright K., Gorringe A. R. 2002; Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 70:3621–3626 [CrossRef]
     [Google Scholar]
  33. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. 2005; MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191–2196 [CrossRef]
     [Google Scholar]
  34. Perrett K. P., Pollard A. J. 2005; Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5:1611–1625 [CrossRef]
     [Google Scholar]
  35. Rappuoli R. 2000; Reverse vaccinology. Curr Opin Microbiol 3:445–450 [CrossRef]
     [Google Scholar]
  36. Rosenstein N. E., Perkins B. A., Stephens D. S., Popovic T., Hughes J. M. 2001; Medical progress: meningococcal disease. N Engl J Med 344:1378–1388 [CrossRef]
     [Google Scholar]
  37. Rouppe van der Voort E., Schuller M., Holst J., de Vries P., Van der Ley P., Van den Dobbelsteen G., Poolman J. 2000; Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine 18:1334–1343 [CrossRef]
     [Google Scholar]
  38. Sexton K., Lennon D., Oster P., Crengle S., Martin D., Mulholland K., Percival T., Reid S., Stewart J., O'Hallahan J. 2004a; The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 117, U1015
  39. Sexton K., Lennon D., Oster P., Aaberge I., Martin D., Reid S., Wong S., O'Hallahan J. 2004b; Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J 117:1 p preceding U1027
    [Google Scholar]
  40. Stephens D. S., Greenwood B., Brandtzaeg P. 2007; Epidemic meningitis, meningococcaemia, and Neisseria meningitidis . Lancet 369:2196–2210 [CrossRef]
     [Google Scholar]
  41. Suker J., Feavers I. M., Corbel M. J., Jones C., Bolgiano B. 2004; Control and lot release of meningococcal group C conjugate vaccines. Expert Rev Vaccines 3:533–540 [CrossRef]
     [Google Scholar]
  42. Thomas M. 2004; Prevention of group B meningococcal disease by vaccination: a difficult task. N Z Med J 117:U1016
     [Google Scholar]
  43. Thompson E. A., Feavers I. M., Maiden M. C. 2003; Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149:1849–1858 [CrossRef]
     [Google Scholar]
  44. Tiwana H., Clow K. J., Hall C., Feavers I. M., Charalambous B. M. 2005; The immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide. Scand J Immunol 62:385–392 [CrossRef]
     [Google Scholar]
  45. Tsang R. S. W., Sill M. L., Skinner S. J., Law D. K. S., Zhou J., Wylie J. 2007; Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000–2006: invasive disease due to non-type B strains. Clin Infect Dis 44:1611–1614 [CrossRef]
     [Google Scholar]
  46. Unkmeir A., Kämmerer U., Stade A., Hübner C., Haller S., Kolb-Mäurer A., Frosch M., Dietrich G. 2002; Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 70:2454–2462 [CrossRef]
     [Google Scholar]
  47. Urwin R., Russell J. E., Thompson E. A., Holmes E. C., Feavers I. M., Maiden M. C. 2004; Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72:5955–5962 [CrossRef]
     [Google Scholar]
  48. Vermont C. L., Van den Dobbelsteen G. P. 2003; Meningococcal serogroup B infections: a search for a broadly protective vaccine. Expert Rev Vaccines 2:673–681 [CrossRef]
     [Google Scholar]
  49. Wedege E., Bolstad K., Aase A., Herstad T. K., McCallum L., Rosenqvist E., Oster P., Martin D. 2007; Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 14:830–838 [CrossRef]
     [Google Scholar]
  50. WHO 1998 Control of Epidemic Meningococcal Disease , WHO practical guidelines, 2nd edn, WHO/EMC/BAC/98.3. Geneva: World Health Organization; http://www.who.int/emc
     [Google Scholar]
  51. Wyle F. A., Artenstein M. S., Brandt B. L., Tramont E. C., Kasper D. L., Altieri P. L., Berman S. L., Lowenthal J. P. 1972; Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126:514–521 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.011189-0
Loading

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error